Bartter's syndrome: physiological and pharmacological studies.

Area of Science:

• Nephrology
• Endocrinology
• Molecular Biology

Background:

• Bartter's syndrome is a rare genetic disorder affecting kidney function.
• Elevated urinary prostaglandin E (iPgE) and electrolyte imbalances are characteristic.
• The exact pathogenesis and role of prostaglandins remain under investigation.

Purpose of the Study:

• To investigate the role of prostaglandins and bradykinin in Bartter's syndrome.
• To evaluate the effects of specific inhibitors on the syndrome's manifestations.

Main Methods:

• Studied six siblings with Bartter's syndrome.
• Administered prostaglandin synthetase inhibitors (indomethacin, ibuprofen, meclofenamate).
• Administered phospholipase inhibitor (mepacrine) and kallikrein inhibitor (aprotinin).
• Monitored urinary iPgE, plasma potassium, renin activity, and natriuresis.
• Assessed tubular sodium reabsorption and water clearance during saline infusion.

Main Results:

• Prostaglandin inhibitors normalized urinary iPgE, increased plasma potassium, and reduced renin activity.
• These inhibitors also abolished exaggerated natriuresis.
• Mepacrine normalized urinary iPgE but did not affect other abnormalities.
• Aprotinin had no significant effect on iPgE or electrolyte balance.
• Proximal tubular sodium reabsorption was normal/increased, but distal sodium reabsorption and free water clearance were decreased.

Conclusions:

• Increased renal prostaglandin E production and hyperbradykininemia may not be primary drivers of Bartter's syndrome.
• The therapeutic effects of prostaglandin synthetase inhibitors appear non-specific.
• An intrarenal defect in sodium transport is a plausible cause, leading to secondary hormonal changes.